Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
The role of cholecystokinin (CCK) has been explored in pancreatic carcinogenesis following pancreatobiliary diversion (PBD), using the specific CCK receptor antagonist CR-1409. Male Wistar rats (n = 80) weighing 70-100 g were given weekly i.p. injections of azaserine (30 mg kg-1 week-1) for 3 consecutive weeks. One week later animals were randomised to receive either PBD or sham PBD and thereafter to receive s.c. injections of either saline or CR-1409 (10 mg kg-1 day-1, 5 days a week). Six months after operation surviving rats were killed as follows: sham + saline 20, PBD + saline 19, sham + CR-1409 14, PBD + CR-1409 11. Cardiac blood was taken for CCK assay and the pancreas was excised for wet weight measurement and quantitative estimation of atypical acinar cell foci (AACF), the precursor of carcinoma. PBD reduced median body weight (3-20% less than shams) but trebled the absolute and relative pancreatic weights (P < 0.001). CR-1409 blunted this adaptive response to PBD, reducing absolute pancreatic weight by 35% (P < 0.005). PBD quadrupled circulating CCK concentrations, regardless of the antagonist treatment. Acidophilic AACF occurred only in rats with PBD. CR-1409 markedly reduced the number of observed acidophilic AACF by 90% (P < 0.001) and the number of foci per pancreas by 93% (P < 0.001). Moreover, CR-1409 reduced the mean focal diameter of each lesion by 18% (P < 0.005), the mean focal volume by 58% (P < 0.05) and the percentage of pancreas occupied by acidophilic foci by 95% (P < 0.001). PBD enhances pancreatic carcinogenesis by causing hypercholecystokininaemia, and CR-1409 largely inhibits this enhancement.
Watanapa
P
P
Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Flaks
B
B
Oztas
H
H
Deprez
P H
PH
Calam
J
J
Williamson
R C
RC
D000818:Animals; D001377:Azaserine; D015904:Biliopancreatic Diversion / Q000009:adverse effects*; D001835:Body Weight / Q000187:drug effects; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000097:blood; D003043:Cocarcinogenesis; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000033:anatomy & histology / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*; D011230:Precancerous Conditions / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D011377:Proglumide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar
D001377:Azaserine; D002766:Cholecystokinin; D011377:Proglumide; C048181:lorglumide